These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 27704468)
21. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Marti RM; Pujol RM; Servitje O; Palou J; Romagosa V; Bordes R; González-Castro J; Miralles J; Gallardo F; Curcó N; Gómez X; Domingo A; Estrach T Leuk Lymphoma; 2003 Jan; 44(1):59-69. PubMed ID: 12691143 [TBL] [Abstract][Full Text] [Related]
22. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. Yoo EK; Cassin M; Lessin SR; Rook AH J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181 [TBL] [Abstract][Full Text] [Related]
23. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma. Sato M; Ishikawa O; Miyachi Y Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042 [TBL] [Abstract][Full Text] [Related]
24. Sézary syndrome without erythroderma. Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic tools in Sezary syndrome. Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046 [TBL] [Abstract][Full Text] [Related]
26. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice. van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578 [TBL] [Abstract][Full Text] [Related]
27. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome. van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192 [TBL] [Abstract][Full Text] [Related]
28. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic. Thompson AK; Killian JM; Weaver AL; Pittelkow MR; Davis MD J Am Acad Dermatol; 2017 Apr; 76(4):683-688. PubMed ID: 28012574 [TBL] [Abstract][Full Text] [Related]
29. Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression. Borcherding N; Voigt AP; Liu V; Link BK; Zhang W; Jabbari A Clin Cancer Res; 2019 May; 25(10):2996-3005. PubMed ID: 30718356 [TBL] [Abstract][Full Text] [Related]
30. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma. LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796 [TBL] [Abstract][Full Text] [Related]
31. The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome. Miyashiro D; Souza BCE; Torrealba MP; Manfrere KCG; Sato MN; Sanches JA Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055124 [TBL] [Abstract][Full Text] [Related]
32. Sezary syndrome cells unlike normal circulating T lymphocytes fail to migrate following engagement of NT1 receptor. Magazin M; Poszepczynska-Guigné E; Bagot M; Boumsell L; Pruvost C; Chalon P; Culouscou JM; Ferrara P; Bensussan A J Invest Dermatol; 2004 Jan; 122(1):111-8. PubMed ID: 14962098 [TBL] [Abstract][Full Text] [Related]
33. Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course. Wu R; Zippin JH; Magro C Cutis; 2014 Feb; 93(2):E18-25. PubMed ID: 24605355 [TBL] [Abstract][Full Text] [Related]
34. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. Devata S; Wilcox RA Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912 [TBL] [Abstract][Full Text] [Related]
35. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Kamijo H; Miyagaki T; Takahashi-Shishido N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S Leukemia; 2020 Mar; 34(3):845-856. PubMed ID: 31712778 [TBL] [Abstract][Full Text] [Related]
36. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Wilcox RA Am J Hematol; 2011 Nov; 86(11):928-48. PubMed ID: 21990092 [TBL] [Abstract][Full Text] [Related]
37. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425 [TBL] [Abstract][Full Text] [Related]
38. EPHA4 is overexpressed but not functionally active in Sézary syndrome. Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612 [TBL] [Abstract][Full Text] [Related]
39. Therapy of cutaneous lymphoma--current practice and future developments. Dummer R; Kempf W; Hess Schmid M; Häffner A; Burg G Onkologie; 2003 Aug; 26(4):366-72. PubMed ID: 12972705 [TBL] [Abstract][Full Text] [Related]
40. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Gibson JF; Huang J; Liu KJ; Carlson KR; Foss F; Choi J; Edelson R; Hussong JW; Mohl R; Hill S; Girardi M J Am Acad Dermatol; 2016 May; 74(5):870-7. PubMed ID: 26874819 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]